Zoetis Inc. $ZTS Shares Purchased by GoalVest Advisory LLC

GoalVest Advisory LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 36.8% in the 2nd quarter, Holdings Channel reports. The firm owned 602 shares of the company’s stock after buying an additional 162 shares during the quarter. GoalVest Advisory LLC’s holdings in Zoetis were worth $94,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after acquiring an additional 189,287 shares in the last quarter. Polen Capital Management LLC grew its stake in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Northern Trust Corp grew its stake in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after acquiring an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after acquiring an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. grew its stake in shares of Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock valued at $725,866,000 after acquiring an additional 312,746 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 1.1%

NYSE:ZTS opened at $147.57 on Tuesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a 50-day simple moving average of $148.08 and a 200 day simple moving average of $153.52. Zoetis Inc. has a one year low of $139.34 and a one year high of $184.40. The company has a market capitalization of $65.40 billion, a price-to-earnings ratio of 25.40, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter last year, the company posted $1.56 earnings per share. Zoetis’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. UBS Group lowered their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday, October 20th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.